ProKidney Confirms Phase 3 Enrollment Progress, Q2 2027 Topline Results, and FDA Alignment for Accelerated Approval

summarizeSummary

ProKidney announced significant progress in its Phase 3 PROACT 1 clinical trial, confirming mid-2026 enrollment completion and Q2 2027 topline results, alongside positive FDA alignment for accelerated approval.

check_boxKey Events

• Phase 3 Enrollment On Track

  The company expects to complete enrollment for the PROACT 1 accelerated approval analysis by mid-2026.

• Pivotal Topline Results Expected

  Pivotal topline results for the PROACT 1 study are anticipated in Q2 2027.

• FDA Alignment Confirmed

  The company reaffirmed FDA agreement on eGFR slope as a surrogate endpoint for accelerated approval, with a 1.5 mL/min/1.73m² effect size being an acceptable demonstration of efficacy.

• Positive Phase 2 Data Highlighted

  Phase 2 REGEN-007 study results showed a 4.6 mL/min/1.73m² improvement in eGFR slope, exceeding the FDA's acceptable threshold for efficacy.

auto_awesomeAnalysis

This filing provides crucial updates on ProKidney's lead product candidate, rilparencel, including being on track to complete Phase 3 PROACT 1 enrollment by mid-2026 and anticipating pivotal topline results in Q2 2027. The company also reiterated FDA alignment on using eGFR slope as a surrogate endpoint for accelerated approval, with Phase 2 data showing a significant improvement that exceeds the FDA's acceptable efficacy demonstration. These updates offer clarity on the development timeline and regulatory path for its core asset.